Shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) shot up 5.6% during mid-day trading on Wednesday . The company traded as high as $22.23 and last traded at $22.23. 132,500 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 187,598 shares. The stock had previously closed at $21.05.
A number of research firms recently issued reports on DCPH. BidaskClub downgraded Deciphera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday. Piper Jaffray Companies lifted their target price on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, June 3rd. They noted that the move was a valuation call. ValuEngine downgraded Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 9th. Canaccord Genuity lowered their target price on Deciphera Pharmaceuticals from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, March 15th. Finally, Zacks Investment Research downgraded Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $43.88.
The stock has a market capitalization of $807.70 million, a price-to-earnings ratio of -7.88 and a beta of 2.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.55 and a quick ratio of 9.55.
In other Deciphera Pharmaceuticals news, CFO Thomas Patrick Kelly sold 13,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $22.93, for a total transaction of $309,555.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 17,073 shares of company stock worth $399,388. Company insiders own 7.02% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Arbitrage SA increased its position in Deciphera Pharmaceuticals by 61,033.3% during the first quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after buying an additional 1,831 shares during the last quarter. Great West Life Assurance Co. Can acquired a new position in Deciphera Pharmaceuticals during the fourth quarter worth approximately $50,000. BlueMountain Capital Management LLC acquired a new position in Deciphera Pharmaceuticals during the first quarter worth approximately $88,000. Rhumbline Advisers boosted its holdings in shares of Deciphera Pharmaceuticals by 53.6% during the fourth quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock worth $241,000 after acquiring an additional 4,000 shares during the period. Finally, State of Wisconsin Investment Board bought a new stake in shares of Deciphera Pharmaceuticals during the first quarter worth approximately $272,000. 58.89% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://weekherald.com/2019/06/12/deciphera-pharmaceuticals-nasdaqdcph-shares-up-5-6.html.
Deciphera Pharmaceuticals Company Profile (NASDAQ:DCPH)
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Further Reading: What is Liquidity?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.